News - Genito-urinary


Current filters:


Popular Filters

10 to 34 of 36 results

Positive data expected for RedHill Biopharma's Crohn's disease candidate


Analysts at Roth Capital Partners have launched coverage of Israel-based specialty pharma company RedHill…

FinancialGenito-urinaryPharmaceuticalRBH-104RedHill BiopharmaResearch

Lilly's ED drug Cialis meets endpoint in LUTS/BPH study


US drug major Eli Lilly (NYSE: LLY) presented results yester day at the annual European Association of…

CialisEli LillyGenito-urinaryMen's HealthPharmaceuticalResearch

Dainippon Sumitomo partners with Nippon Shinyaku for urology drug AMP-986


Japanese drugmakers Dainippon Sumitomo Pharma (TYO: 4506) and Nippon Shinyaku (TYO: 4516) have concluded…

AMP-986Asia-PacificDainippon Sumitomo PharmaGenito-urinaryLicensingNippon ShinyakuPharmaceutical

Research results for Pfizer's Chantix, Pristiq and Toviaz


Global drugs behemoth Pfizer (NYSE: PFE) last week released a batch of new clinical trial data relating…


FDA approves Allergan's Botox for OAB and NuPathe's Zecuity for migraine


US drugmaker Allergan (NYSE: AGN) says that the US Food and Drug Administration has approved its Botox…

AllerganBotoxGenito-urinaryNeurologicalNorth AmericaNuPathePharmaceuticalRegulationZecuity

Astellas' Betmiga Oked in EU for overactive bladder


The European subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) has received approval from…

Astellas PharmaBetmigaEuropeGenito-urinarymirabegronPharmaceuticalRegulation

Watson gets FDA approval for generic Sanctura XR and Avapro


US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has received approval from the US Food and Drug…

AllerganAvaproCardio-vascularGenericsGenito-urinaryNorth AmericaRegulationSanctura XRSanofiWatson Pharmaceuticals

Astellas links with KEK on tropical diseases; Upgraded by CS analysts


Japanese drug major Astellas Pharma (TYO: 4503) has entered into a collaboration with the High Energy…

Astellas PharmaFinancialGenito-urinaryMyrbetriqOncologyPharmaceuticalResearchTropical diseasesXtandi

PDUFA Action Date for Astellas enzalutamide; Urogenix facility to close


The US Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date…

Astellas PharmaenzalutamideGenito-urinaryMedivationOncologyPharmaceuticalRegulationResearchUrogenixVaccines

Positive Ph IV data for Pfizer and UCB's Toviaz


Global drugs behemoth Pfizer (NYSE: PFE) has released positive Phase IV study results assessing the efficacy…


FDA approves Astellas' Myrbetriq for overactive bladder


The US Food and Drug Administration has approved Japanese drug major Astellas Pharma's (TYO: 4503) Myrbetriq…

Astellas PharmaGenito-urinarymirabegronMyrbetriqNorth AmericaPharmaceuticalRegulation

Kyowa Hakko debuts Poteligeo in Japan; co-promotes Minirinmelt with Ferring


Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) says that it has launched Poteligeo (mogamulizumab)…

Asia-PacificFerring PharmaceuticalsGenito-urinaryKyowa Hakko KirinMarkets & MarketingMinirinmeltOncologyPharmaceuticalPoteligeo

AstraZeneca to acquire Ardea Bio for $1.26 billion


In line with its stated policy of making strategic, rather than mega, acquisitions, Anglo-Swedish drug…

Anti-Arthritics/RheumaticsArdea BiosciencesAstraZenecaBiotechnologyGenito-urinarylesinuradMergers & AcquisitionsPharmaceutical

Pharma giants set to lose dominance in urological disorders market


Major pharmaceutical companies are predicted to lose their footing in the urological disorders market…

Genito-urinaryMarkets & MarketingPatentsPharmaceutical

Menarini extends febuxostat accord to more regions


Japanese drugmaker Teijin Pharma and privately-owned Italian pharmaceutical company Menarini have signed…


FDA advisory panel backs Astellas OAB drug mirabegron


The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) said last week that the Reproductive…

Genito-urinarymirabegronNorth AmericaPharmaceuticalRegulation

Watson confirms Lumigan and Latisse patent challenges; favorable Sanctura ruling


US generic drugmaker Watson Pharmaceuticals (NYSE: WPI) has confirmed that its subsidiary, Watson Laboratories,…

AllerganGenericsGenito-urinaryLatisseLegalLumiganOphthalmicsPatentsSanctura XRWatson Pharmaceuticals

Botox shows efficacy in idiopathic overactive bladder, says Allergan


USA-based Allergan (NYSE: AGN) announced that two Phase III clinical trials of Botox (onabotulinumtoxinA),…


10 to 34 of 36 results

Back to top